Combining a homogenous KIM-1-DM1 antibody drug conjugate with sunitinib in renal cell carcinoma
Liya Thurakkal, Krishna Velayutham, Binayak Sarkar…·Tanmoy Saha
This study combines a homogenous KIM-1-targeted ADC with sunitinib to treat RCC, showing synergistic antitumor efficacy in a mouse model.